Cargando…

Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3

Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus, OPV evolves rapidly to lose attenuating determinants critical to the reacquisition of virulence(1–3) resulting i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeh, Ming Te, Smith, Matthew, Carlyle, Sarah, Konopka-Anstadt, Jennifer L., Burns, Cara C., Konz, John, Andino, Raul, Macadam, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322712/ https://www.ncbi.nlm.nih.gov/pubmed/37316671 http://dx.doi.org/10.1038/s41586-023-06212-3

Ejemplares similares

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
por: Wahid, Rahnuma, et al.
Publicado: (2022)

Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials
por: Wahid, Rahnuma, et al.
Publicado: (2022)

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
por: Konopka-Anstadt, Jennifer L., et al.
Publicado: (2020)

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study
por: Van Damme, Pierre, et al.
Publicado: (2019)

Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine
por: Konz, John O., et al.
Publicado: (2021)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine
por: Manukyan, Hasmik, et al.
Publicado: (2022)

Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
por: Yeh, Ming Te, et al.
Publicado: (2020)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
por: Sáez-Llorens, Xavier, et al.
Publicado: (2021)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination
por: Tan, Susanna K., et al.
Publicado: (2020)

Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
por: Wahid, Rahnuma, et al.
Publicado: (2021)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Improvement of the qmosRT-PCR Assay and Its Application for the Detection and Quantitation of the Three Serotypes of the Novel Oral Polio Vaccine in Stool Samples
por: Manukyan, Hasmik, et al.
Publicado: (2023)

Poliovirus RNA Replication Requires Genome Circularization through a Protein–Protein Bridge
por: Herold, Jens, et al.
Publicado: (2001)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Identification and Manipulation of the Molecular Determinants Influencing Poliovirus Recombination
por: Runckel, Charles, et al.
Publicado: (2013)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

An RNA Element at the 5′-End of the Poliovirus Genome Functions as a General Promoter for RNA Synthesis
por: Vogt, Dorothee A., et al.
Publicado: (2010)

Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines
por: Fox, Helen, et al.
Publicado: (2017)

Update on Vaccine-Derived Polioviruses — Worldwide, July 2012–December 2013
por: Diop, Ousmane M., et al.
Publicado: (2014)

Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023
por: Davlantes, Elizabeth, et al.
Publicado: (2023)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Direct detection of polioviruses using a recombinant poliovirus receptor
por: Gerloff, Nancy, et al.
Publicado: (2021)

Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2
por: Manukyan, Hasmik, et al.
Publicado: (2021)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Update on Vaccine-Derived Polioviruses — Worldwide, January 2014–March 2015
por: Diop, Ousmane M., et al.
Publicado: (2015)

Mapping Attenuation Determinants in Enterovirus-D68
por: Yeh, Ming Te, et al.
Publicado: (2020)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Update on Vaccine-Derived Polioviruses — Worldwide, January 2016–June 2017
por: Jorba, Jaume, et al.
Publicado: (2017)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

III. Factors Influencing the Acceptance of Oral Poliovirus Vaccine
por: Cohart, Edward M., et al.
Publicado: (1962)

Update on Vaccine-Derived Polioviruses — Worldwide, January 2017–June 2018
por: Jorba, Jaume, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nl9olvgsukvhs4efa6s12cp0te